잠시만 기다려 주세요. 로딩중입니다.

Phase II Trial of Epigallocatechin-3-Gallate in Acute Radiation-Induced Esophagitis for Esophagus Cancer

Journal of Medicinal Food 2020년 23권 1호 p.43 ~ 49
Li Xiaoling, Xing Ligang, Zhang Yujun, Xie Peng, Zhu Wanqi, Meng Xiangjiao, Wang Yinxia, Kong Lingling, Zhao Hanxi, Yu Jinming,
소속 상세정보
 ( Li Xiaoling ) - Shandong University School of Medicine
 ( Xing Ligang ) - Shandong First Medical University and Shandong Academy of Medical Sciences Shandong Cancer Hospital and Institute Department of Radiation Oncology
 ( Zhang Yujun ) - Yishui People Hospital Department of Oncology
 ( Xie Peng ) - Shandong First Medical University and Shandong Academy of Medical Sciences Shandong Cancer Hospital and Institute Department of Radiation Oncology
 ( Zhu Wanqi ) - Shandong First Medical University and Shandong Academy of Medical Sciences Shandong Cancer Hospital and Institute Department of Radiation Oncology
 ( Meng Xiangjiao ) - Shandong First Medical University and Shandong Academy of Medical Sciences Shandong Cancer Hospital and Institute Department of Radiation Oncology
 ( Wang Yinxia ) - Shandong First Medical University and Shandong Academy of Medical Sciences Shandong Cancer Hospital and Institute Department of Radiation Oncology
 ( Kong Lingling ) - Shandong First Medical University and Shandong Academy of Medical Sciences Shandong Cancer Hospital and Institute Department of Radiation Oncology
 ( Zhao Hanxi ) - Shandong First Medical University and Shandong Academy of Medical Sciences Shandong Cancer Hospital and Institute Department of Radiation Oncology
 ( Yu Jinming ) - Shandong First Medical University and Shandong Academy of Medical Sciences Shandong Cancer Hospital and Institute Department of Radiation Oncology

Abstract


Acute radiation-induced esophagitis (ARIE) is among the most serious form of toxicities associated with definitive radiotherapy or chemoradiotherapy used for treatment of patients with esophageal cancer. Our preliminary phase I and II trials of lung cancer patients who received radiotherapy indicated epigallocatechin-3-gallate (EGCG) as a promising therapeutic option against ARIE. Therefore, we conducted a prospective phase II study to validate the efficacy and safety of EGCG in the treatment of ARIE. The patients who received chemoradiotherapy or definitive radiotherapy for treatment of esophageal cancer in the Shandong Cancer Hospital and Institute in China were enrolled for the present study. EGCG (440?μM) was administered with first onset of ARIE and then at weeks after final radiotherapy. The patients were monitored every week for dysphagia, Radiation Therapy Oncology Group (RTOG) score, and esophagitis-related pain. Moreover, tumor response and the effect on survival following the treatment were also evaluated. Comparison of the RTOG score in the first, second, third, fourth, fifth, and even sixth week after EGCG prescription and the first and second week after radiotherapy with baseline indicates a significant reduction. The tumor response rate was 86.3%. The overall survival rate in 1, 2, and 3 years was found to be 74.5%, 58%, and 40.5%. Oral administration of EGCG solution seems to be feasible for treating ARIE in patients with esophageal cancer who receive radiation therapy. EGCG might be an ARIE-reliever without compromising the efficacy of radiation therapy. A randomized study with a control group is needed for further evaluation.

키워드

acute radiation-induced esophagitis (ARIE); definitive radiation therapy; epigallocatechin-3-gallate (EGCG); esophageal cancer

원문 및 링크아웃 정보

등재저널 정보